HIPAA and Co‑Branding: Compliance Essentials for Healthcare Marketing Partnerships

Co-branding can elevate healthcare marketing partnerships, but HIPAA sets strict guardrails when protected health information (PHI) touches marketing communications. This guide explains how to partner confidently, when written authorization is required, how exceptions work, and how business associate agreements and de-identified data support compliant execution—without slowing growth.

HIPAA Marketing Definition

What HIPAA calls “marketing”

Under HIPAA, marketing is any communication that encourages a person to purchase or use a product or service. If a campaign promotes a third party’s offerings—or promotes your own offerings in a way that relies on PHI outside permitted activities—it is generally “marketing.”

Common marketing communications that trigger HIPAA analysis include co-branded emails, targeted ads built from patient lists, sponsored newsletters, and remarketing that uses identifiers tied to a patient’s care.

What is not marketing

Not all outreach is “marketing.” Communications for treatment (for example, recommending a device to a specific patient), certain healthcare operations (descriptions of your own health-related products, benefits, or network), and case management or care coordination are outside the marketing definition—so long as you do not receive financial remuneration from a third party whose product is being described.

Authorization Requirements for Marketing

When you must obtain written authorization

• You use or disclose PHI to promote a third party’s product or service, including in co-branded campaigns.
• You receive financial remuneration from a third party to send a communication that promotes that party’s product or service.
• You disclose PHI to a partner or agency so they can build audiences, personalize messaging, or measure a campaign.
• You engage in activities that constitute a sale of PHI or its use for marketing beyond permitted exceptions.

Authorization must be valid and specific. A blanket consent buried in intake forms does not cover marketing that uses PHI.

What a valid authorization includes

• Clear description of the PHI to be used or disclosed and for what marketing purpose.
• The name of the disclosing party and all recipients (including co-brand partners and vendors).
• An expiration date or event, plus the patient’s right to revoke.
• A statement that financial remuneration is received, when applicable.
• The patient’s signature and date. Keep records and honor revocations promptly.

Exceptions to Marketing Authorization

• Face-to-face communications: In-person recommendations or discussions with a patient do not require authorization.
• Promotional gifts of nominal value: Items like pens or brochures handed out in person are permitted.
• Treatment communications: Product or service recommendations to an individual as part of their care are allowed.
• Healthcare operations: Descriptions of your own health-related products or benefits, without third-party financial remuneration, can be sent without authorization.
• Refill reminders and adherence support: Limited communications about a currently prescribed drug or biologic are permitted if any payment received is reasonably related to the cost of making the communication.

If an exception applies but you accept financial remuneration from the third party being promoted, you generally lose the exception and must obtain written authorization.

Co-Branding with PHI

When co-branding stays outside HIPAA

Brand‑only collaborations—such as a joint landing page or general ads that do not use or disclose PHI—do not invoke HIPAA marketing rules. Use broad targeting and public data only, and do not upload patient lists or engagement data derived from care.

When co-branding uses PHI

Co-branded campaigns that segment audiences by diagnosis, appointment history, plan eligibility, or any attribute drawn from PHI require careful handling. If PHI is used internally to target or externally disclosed to the partner or platforms, you likely need written authorization, and involved vendors may need business associate agreements.

Design patterns for compliant co-branding

• Authorize before you personalize: If the campaign’s value depends on PHI-driven relevance, secure patient authorization first.
• Minimize and compartmentalize: Share only the minimum necessary PHI; keep clinical data separate from marketing data flows.
• Avoid impermissible disclosures: Do not allow partner pixels or SDKs on appointment pages, patient portals, or forms that capture PHI.
• Document value flows: Track whether any financial remuneration supports the campaign; disclosures must appear in authorizations when applicable.

Third-Party Promotions Compliance

Giveaways, referrals, and paid promotions

• Do not condition eligibility on providing PHI beyond what is necessary to administer the promotion.
• If a promotion uses PHI to target or contact participants, obtain written authorization and list all recipients of PHI (partners, agencies, platforms).
• Use HIPAA-capable tools where PHI is involved; platforms that cannot sign business associate agreements should not receive PHI.
• For testimonials or endorsements that reveal PHI, secure a specific authorization covering the disclosure and reuse.

Digital tracking and audiences

• Treat hashed or tokenized patient identifiers as PHI if derived from PHI; do not upload to ad platforms without authorization.
• Disable or isolate third-party trackers on pages where PHI may be collected (e.g., symptom checkers, patient intake forms).
• Use first-party analytics or HIPAA-aligned vendors under business associate agreements for measurement that touches PHI.

Use of De-Identified Data

What counts as de-identified data

HIPAA recognizes two methods: the Safe Harbor method (removing 18 types of identifiers, including names, exact addresses, contact numbers, device IDs, full-face photos, and precise dates) and Expert Determination (a qualified expert documents that re-identification risk is very small). Properly de-identified data is not PHI.

How to use de-identified data safely in marketing

• Publish insights at aggregate levels; avoid small-cell counts that could enable re-identification.
• Prohibit re-identification and downstream linkage in contracts with partners and platforms.
• Maintain a robust de-identification workflow with quality checks and independent review.
• Do not mix de-identified data with other datasets in ways that raise re-identification risk; rerun expert assessments if datasets change.

If any identifier remains or new linkage occurs, treat the dataset as PHI and apply full HIPAA safeguards.

Business Associate Agreements for Marketing

When a vendor is your business associate

A vendor becomes a business associate when it creates, receives, maintains, or transmits PHI for you. Examples include email service providers storing patient lists, marketing automation that uses PHI-based segments, call centers handling patient inquiries, and analytics providers measuring PHI-based campaigns.

What to include in business associate agreements

• Permitted uses and disclosures tied to defined marketing communications.
• Administrative, physical, and technical safeguards; breach reporting timelines.
• Subcontractor flow-down requirements so downstream vendors also sign BAAs.
• Minimum necessary standards, data retention limits, and secure return or destruction of PHI.
• Prohibitions on sale of PHI and restrictions on combining PHI with other data for profiling.

Operational tips

• Inventory data flows for each campaign; map where PHI is created, stored, and transmitted.
• Segment environments: keep PHI-enabled workflows separate from general brand marketing.
• Train teams on when healthcare operations messaging is allowed and when written authorization is mandatory.
• Review notices of privacy practices so they align with actual marketing practices.

Conclusion

HIPAA and co-branding can coexist when you classify each outreach correctly, obtain written authorization whenever PHI supports marketing communications or financial remuneration is involved, leverage de-identified data appropriately, and bind vendors with strong business associate agreements. Build campaigns on minimum necessary data and clear documentation, and you can scale compliant healthcare marketing partnerships with confidence.

FAQs.

What qualifies as marketing under HIPAA?

A communication is marketing if it encourages someone to purchase or use a product or service. Promoting a partner’s offering, or promoting your own offering using PHI beyond permitted treatment or healthcare operations activities, generally qualifies. Face-to-face discussions and nominal gifts are exceptions, and some treatment and operations messages are allowed when no third-party financial remuneration is involved.

When is patient authorization required for co-branding?

You need written authorization when PHI is used to target, personalize, or measure a co-branded campaign, when PHI is disclosed to the partner or platforms, or when you receive financial remuneration from the partner for the outreach. If the campaign does not use or disclose PHI, HIPAA marketing authorization is not required.

How can de-identified data be used in marketing?

Once data is properly de-identified under Safe Harbor or Expert Determination, it is no longer PHI and may be used for audience insights, content planning, and aggregated reporting. Maintain contractual prohibitions on re-identification, monitor linkage risks, and revert to PHI rules if identifiers are reintroduced.

What are the risks of non-compliance with HIPAA in marketing?

Risks include civil penalties, corrective action plans, investigations, reputational damage, and disruption to campaigns if data flows must be halted. Failures often involve unapproved disclosures to partners or ad platforms, use of PHI without written authorization, or vendors operating without business associate agreements.